Skip to main content

Table 1 Characteristics of cancer patients who die from cancer (cases) compared with controls, by cancer site

From: Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts

  Breast cancer   Colorectal cancer   Prostate cancer  
  Cases Controls P Cases Controls P Cases Controls P
  number (%) number (%)   number (%) number (%)   number (%) number (%)  
Year of diagnosis          
  1998 to 2000 500 (35) 2,466 (35) N.A. 379 (25) 1,842 (25) N.A. 396 (33) 1,941 (33) N.A.
  2001 to 2003 518 (36) 2,570 (36)   564 (37) 2,721 (37)   461 (39) 2,281 (39)  
  2003 to 2006 417 (29) 2,070 (29)   568 (38) 2,728 (37)   327 (28) 1,627 (28)  
Age at diagnosis (years)          
  <50 339 (24) 1,667 (23) N.A. 90 (6) 330 (5) N.A. 6 (1) 20 (0) N.A.
  50 to 59 286 (20) 1,430 (20)   226 (15) 1,117 (15)   71 (6) 351(6)  
  60 to 69 273 (19) 1,365 (19)   401 (27) 2,001 (27)   280 (24) 1,400 (24)  
  70 to 79 318 (22) 1,588 (22)   496 (33) 2,472 (34)   532 (45) 2,660 (45)  
  ≥ 80 219 (15) 1,056 (15)   298 (20) 1,371 (19)   295 (25) 1,418 (24)  
Male 0 (0) 0 (0) N.A. 871 (58) 4,231 (58) N.A. 1,184(100) 5,849 (100) N.A.
Exposure period (years):          
Mean (sd) 3.9 (2.3) 3.9 (2.3) N.A. 2.8 (1.6) 2.9 (1.7) N.A. 3.8 (2.2) 3.7 (2.2) N.A.
Range 1.0 to 12.8 1.0 to 12.8 N.A. 1.0 to 10.5 1.0 to 10.5 N.A. 1.0 to 11.9 1.0 to 11.9  
Stage:1 72 (11) 1,471 (43) <0.001 61 (6) 1,044 (18) <0.001    
  2 402 (61) 1,676 (49)   275 (25) 2,496 (44)     
  3 116 (18) 220 (6)   558 (51) 1,981 (35)     
  4 64 (10) 40 (1)   203 (19) 195 (3)     
  Missing 781 3,699   414 1,575     
Grade:Well 54 (6) 751 (19)   81 (7) 562 (9) <0.001 34 (4) 538 (13) <0.001
  Moderate 377 (41) 1,900 (49)   889 (75) 4,894 (78)   217 (28) 2,067 (48)  
  Poor 492 (53) 1,217 (31)   208 (17) 818 (13)   516 (67) 1,683 (39)  
  Missing 512 3,280   333 1017   417 1561  
Treatment within six months of diagnosis          
  Chemotherapy 573 (40) 1,611 (23) <0.001 651 (43) 1,916 (26) <0.001 49 (4) 137 (2) <0.001
  Radiotherapy 700 (49) 3,355 (47) 0.22 302 (20) 1,066 (15) <0.001 246 (21) 1,276 (22) 0.48
  Surgery 1,087 (76) 5,982 (84) <0.001 1,214 (80) 65,15 (89) <0.001    
  Tamoxifen therapy 709 (49) 4,610 (65) <0.001       
  Androgen therapy        976 (82) 3,450 (59) <0.001
  Radical prostatectomya        20 (2) 331 (8) <0.001
Smoking prior to diagnosis    0.03    0.01    <0.001
  Non-smoker 710 (60) 3,827 (64)   640 (51) 3,138 (52)   453 (47) 2,541 (52)  
  Ex-smoker 226 (19) 1,072 (18)   365 (29) 1,885 (31)   331 (34) 1,660 (34)  
  Current smoker 249 (21) 1,094 (18)   249 (20) 983 (16)   185 (19) 674 (14)  
  Missing 250 1,113   257 1285   215 974  
BMI prior to diagnosis    0.01    0.66    0.05
  Mean (sd) 26.6 (5.5) 26.2 (5.1)   26.5 (4.7) 26.6 (4.8)   26.4 (4.0) 26.1 (3.7)  
  Missing 386 1,633   412 1,810   302 1,362  
Alcohol prior to diagnosis    0.58    0.47    0.37
  Alcohol consumer 831 (80) 4,333 (81)   950 (87) 4,585 (86)   791 (89) 4,047 (90)  
  Missing 401 1,779   420 1,977   298 1366  
Comorbidity (prior to diagnosis or during follow-up time)          
  Cerebrovascular 89 (6) 383 (5) 0.53 117 (8) 493 (7) 0.19 124 (10) 509 (9) 0.07
  C.P.D. 264 (18) 1,247 (18) 0.60 236 (16) 1295 (18) 0.06 229 (19) 1,110 (19) 0.80
  C.H.D. 60 (4) 249 (4) 0.68 91 (6) 367 (5) 0.13 108 (9) 395 (7) 0.01
  Diabetes 126 (9) 468 (7) 0.02 192 (13) 866 (12) 0.21 141 (12) 619 (11) 0.17
  Myocardial infarction 26 (2) 148 (2) 0.74 104 (7) 454 (6) 0.32 130 (11) 522 (9) 0.03
  Peptic ulcer disease 39 (3) 184 (3) 0.79 111 (7) 477 (7) 0.19 77 (7) 440 (8) 0.18
  P.V.D. 51 (4) 165 (2) 0.003 64 (4) 331 (5) 0.70 113 (10) 396 (7) 0.001
  Renal disease 78 (5) 382 (5) 0.92 107 (7) 478 (7) 0.45 138 (12) 509 (9) 0.001
  Rheumatological 76 (5) 330 (5) 0.35 55 (4) 272 (4) 0.82 37 (3) 287 (5) 0.01
  1. aExcludes cancer registries without available data. C.P.D., chronic pulmonary disease; C.H.D., congestive heart disease; N.A., not applicable; P.V.D., peripheral vascular disease; sd, standard deviation.